GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

→ GSK’s Vi­iV has snared a Eu­ro­pean ap­proval for Ju­lu­ca, which the phar­ma gi­ant touts as the first 2-drug, once-dai­ly, sin­gle pill reg­i­men OK’d for HIV. The drug is a com­bi­na­tion of Vi­iV’s do­lute­gravir 50mg with J&J’s rilpivirine 25mg. “The Eu­ro­pean Com­mis­sion De­ci­sion for Ju­lu­ca is very pos­i­tive news for peo­ple liv­ing with HIV (PL­HIV) across Eu­rope, who will now have the op­por­tu­ni­ty to main­tain their vi­ral sup­pres­sion with a com­plete treat­ment reg­i­men com­posed of on­ly two drugs with­in a sin­gle-pill,” said Vi­iV CEO Deb­o­rah Wa­ter­house.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER